Discover
DNLI
Denali Therapeutics Inc.
25.98
1 x 25.96
1 x 28.00
bid
ask
+
0.26
1.01%
1 @ 04:00 PM
25.90 -0.08 (0.31%)
| Ytd | 57.36% | |
| 1y | 86.24% |
25.61
day range
26.18
12.58
52 week range
26.36
| Open | 25.72 | Prev Close | 25.72 | Low | 25.61 | High | 26.18 | Mkt Cap | 4.12B |
| Vol | 1.17M | Avg Vol | 1.80M | EPS | -2.88 | P/E | N/A | Forward P/E | -10.38 |
| Beta | 1.01 | Short Ratio | 8.17 | Inst. Own | 100.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 20.79 | 200-d Avg | 18.78 | 1yr Est | 33.93 |
| Income Statement | |||
| Operating Expenses | 137.36M | ||
| Research and Development Expense | 103.85M | ||
| Selling, General and Administrative Expense | 33.51M | ||
| Operating Income | -137.36M | ||
| Net Income | -128.45M | ||
| Net Income Common Stock | -128.45M | ||
| Net Income Common Stock (USD) | -128.45M | ||
| Consolidated Income | -128.45M | ||
| Earnings per Basic Share | -0.69 | ||
| Earnings per Basic Share (USD) | -0.69 | ||
| Earnings per Diluted Share | -0.69 | ||
| Earning Before Interest & Taxes (EBIT) | -128.45M | ||
| Earning Before Interest & Taxes (USD) | -128.45M | ||
| Weighted Average Shares | 186.64M | ||
| Weighted Average Shares Diluted | 186.64M | ||
| Balance Sheet | |||
| Cash and Equivalents | 387.63M | ||
| Cash and Equivalents (USD) | 387.63M | ||
| Investments | 663.84M | ||
| Investments Current | 600.06M | ||
| Investments Non-Current | 63.79M | ||
| Current Assets | 1.02B | ||
| Property, Plant & Equipment Net | 117.27M | ||
| Total Assets | 1.27B | ||
| Total Debt | 229.77M | ||
| Current Liabilities | 110.16M | ||
| Debt Non-Current | 229.77M | ||
| Total Liabilities | 339.93M | ||
| Accumulated Retained Earnings (Deficit) | -2.18B | ||
| Accumulated Other Comprehensive Income | -682.00K | ||
| Shareholders Equity | 926.10M | ||
| Shareholders Equity (USD) | 926.10M | ||
| Assets Non-Current | 243.27M | ||
| Total Debt (USD) | 229.77M | ||
| Goodwill and Intangible Assets | 36.00M | ||
| Liabilities Non-Current | 229.77M | ||
| Trade and Non-Trade Payables | 40.38M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 3.76M | ||
| Net Cash Flow from Financing | 219.04M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 182.30M | ||
| Capital Expenditure | -2.47M | ||
| Issuance (Purchase) of Equity Shares | 19.06M | ||
| Issuance (Repayment) of Debt Securities | 199.98M | ||
| Net Cash Flow from Investing | 94.46M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 96.93M | ||
| Net Cash Flow from Operations | -131.20M | ||
| Share Based Compensation | 23.09M | ||